ViroVax
Biotechnology Research • 
2029 Becker Dr, Lawrence, United States • 1-10 Employees
Company overview
| Headquarters | 2029 Becker Dr, Lawrence, Kansas 66047, US |
| Website | |
| NAICS | 541714 |
| SIC | 738 |
| Employees | 1-10 |
Key Contact at ViroVax
Sunil David
Chief Executive Officer
ViroVax Email Formats
ViroVax uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@virovaxllc.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@virovaxllc.com | 100% |
About ViroVax
ViroVax is a biotechnology company focused on research and development of vaccines, adjuvants, and therapeutics to protect and treat people from infectious diseases, including zika, west nile, dengue, and sars-cov-2.
ViroVax revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
ViroVax has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
ViroVax has never raised funding before.
ViroVax Tech Stack
Discover the technologies and tools that power ViroVax's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
Security
Ecommerce
JavaScript frameworks
Security
Miscellaneous
JavaScript libraries
Ecommerce
JavaScript libraries
CMS
Puerto Rico
India
United KingdomFrequently asked questions
4.8
40,000 users
